Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin effect on thyroid function tests in prediabetes and type 2 diabetes
IRCT20090317001774N10Phase 2Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in prediabetes and type 2 diabetes mellitus (T2DM), sponsored by Kerman University of Medical Sciences. Primary endpoints: TSH after 3 months, Total T3 after 3 months and 2 more. Started Mar 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
prediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20090317001774N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090317001774N10.